An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.

TPS3117Background: PD-1 blockade showed promising efficacy in facilitating tumor shrinkage for broad type of cancer patients, but objective response rates are very limited. The antitumor potential ...